Advisor Partners LLC cut its stake in shares of Icon Plc (NASDAQ:ICLR) by 11.5% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,510 shares of the medical research company’s stock after selling 196 shares during the period. Advisor Partners LLC’s holdings in Icon were worth $222,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently modified their holdings of the company. SRS Capital Advisors Inc. bought a new position in shares of Icon during the second quarter worth approximately $47,000. UBS Asset Management Americas Inc. boosted its holdings in shares of Icon by 30.9% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 326 shares of the medical research company’s stock valued at $50,000 after acquiring an additional 77 shares in the last quarter. Coastal Capital Group Inc. acquired a new stake in shares of Icon during the 2nd quarter valued at $78,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of Icon during the 2nd quarter valued at $172,000. Finally, DekaBank Deutsche Girozentrale boosted its holdings in shares of Icon by 72.7% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 1,328 shares of the medical research company’s stock valued at $201,000 after acquiring an additional 559 shares in the last quarter. 83.53% of the stock is owned by hedge funds and other institutional investors.
ICLR stock opened at $139.69 on Wednesday. The stock has a 50-day moving average price of $148.31 and a 200-day moving average price of $146.88. Icon Plc has a 1-year low of $118.10 and a 1-year high of $165.13. The company has a current ratio of 2.07, a quick ratio of 2.07 and a debt-to-equity ratio of 0.28. The firm has a market cap of $7.64 billion, a PE ratio of 22.21, a price-to-earnings-growth ratio of 1.95 and a beta of 0.67.
ICLR has been the topic of several recent research reports. Mizuho raised their price objective on Icon from $160.00 to $170.00 and gave the company a “buy” rating in a report on Thursday, July 25th. KeyCorp lifted their target price on Icon from $157.00 to $165.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. Zacks Investment Research raised Icon from a “sell” rating to a “hold” rating in a report on Wednesday. BidaskClub downgraded Icon from a “buy” rating to a “hold” rating in a report on Monday, September 30th. Finally, UBS Group cut their target price on Icon from $171.00 to $158.00 and set a “neutral” rating on the stock in a report on Friday, October 18th. Five research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $163.43.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Story: 52-Week High/Low
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.